Literature DB >> 17082610

Distinct molecular program imposed on CD4+ T cell targets by CD4+CD25+ regulatory T cells.

Teresa L Sukiennicki1, Deborah J Fowell.   

Abstract

CD4+CD25+ regulatory T cells (Tregs) are key modulators of immunity, but their mechanism of action is unclear. To elucidate the molecular consequences of Treg encounter, we analyzed changes in gene expression in CD4+ T cell targets activated in the presence or absence of CD4+CD25+ Tregs. Tregs did not alter the early activation program of CD4+ T cells, but had reversed many of the activation-induced changes by 36 h. It is not known whether Tregs simply induce a set of transcriptional changes common to other nonproliferative states or whether instead Tregs mediate a distinct biological activity. Therefore, we compared the gene profile of T cells following Treg encounter with that of T cells made anergic, TGF-beta-treated, or IL-2-deprived; all possible modes of Treg action. Strikingly, all genes down-regulated in suppressed cells were indeed common to these nonproliferative states. In contrast, Treg encounter led to elevated expression of a unique set of genes in the target T cells. Although different from the nonproliferative states tested, the Treg-imposed gene program is exemplified by expression of many genes associated with growth arrest or inhibition of proliferation. We suggest that Tregs function by the induction of a distinct set of negative regulatory factors that initiate or maintain target T cells in a nonproliferative state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082610     DOI: 10.4049/jimmunol.177.10.6952

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Transient modification within a pool of CD4 T cells in the maternal spleen.

Authors:  Elizabeth A Bonney; Michelle T Shepard; Peyman Bizargity
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  CD4 T cell-intrinsic role for the T helper 17 signature cytokine IL-17: Effector resistance to immune suppression.

Authors:  Michael P Crawford; Sushmita Sinha; Pranav S Renavikar; Nicholas Borcherding; Nitin J Karandikar
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

Review 3.  Transcriptional regulation of T cell tolerance.

Authors:  Sanmay Bandyopadhyay; Noemí Soto-Nieves; Fernando Macián
Journal:  Semin Immunol       Date:  2007-03-26       Impact factor: 11.130

Review 4.  Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target.

Authors:  Dorothy K Sojka; Yu-Hui Huang; Deborah J Fowell
Journal:  Immunology       Date:  2008-03-14       Impact factor: 7.397

Review 5.  Regulation of immunity at tissue sites of inflammation.

Authors:  Dorothy K Sojka; Christopher A Lazarski; Yu-Hui Huang; Irina Bromberg; Angela Hughson; Deborah J Fowell
Journal:  Immunol Res       Date:  2009-01-31       Impact factor: 2.829

6.  CLIC4 is a tumor suppressor for cutaneous squamous cell cancer.

Authors:  K Stephen Suh; Mariam Malik; Anjali Shukla; Andrew Ryscavage; Lisa Wright; Kasey Jividen; John M Crutchley; Rebecca A Dumont; Ester Fernandez-Salas; Joshua D Webster; R Mark Simpson; Stuart H Yuspa
Journal:  Carcinogenesis       Date:  2012-03-01       Impact factor: 4.944

Review 7.  beta2-integrins in demyelinating disease: not adhering to the paradigm.

Authors:  Xianzhen Hu; Jillian E Wohler; Kari J Dugger; Scott R Barnum
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

8.  Cutting edge: regulatory T cells do not require stimulation through their TCR to suppress.

Authors:  Andrea L Szymczak-Workman; Creg J Workman; Dario A A Vignali
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

9.  LFA-1 is critical for regulatory T cell homeostasis and function.

Authors:  Jillian Wohler; Dan Bullard; Trent Schoeb; Scott Barnum
Journal:  Mol Immunol       Date:  2009-05-09       Impact factor: 4.407

10.  Immune tolerance in liver disease.

Authors:  Ian N Crispe
Journal:  Hepatology       Date:  2014-09-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.